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Introduction to and aim of this report 
This report provides an update on drug-related deaths in Europe (EMCDDA, 2019a, 2019b). 
It is primarily based on presentations and discussions held at the annual 2-day meeting of 
the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) expert network on 
drug-related deaths in Lisbon on 21 and 22 October 2019 (EMCDDA, 2019b). The meeting 
brought together experts and representatives from over 40 countries and provided a platform 
At a glance: a summary of key points  
Overdose deaths: a very high burden of preventable premature deaths 
• Over 8 300 deaths involving one or more illicit drugs were reported in 2018 in the European 
Union. This estimate rises to over 9 200 deaths when Norway and Turkey are included. Men 
account for three quarters of drug-induced deaths. Most of the deaths were very premature, 
affecting people in their thirties and forties. Multiple drug toxicity is implicated in most cases. 
Opioids: the main driver of fatal overdoses in Europe 
• Opioids, often heroin, or opioid substitution treatment medicines, such as methadone and 
buprenorphine, are involved in 80-90 % of drug-related deaths overall, although differences 
between countries exist. 
• Deaths associated with fentanyl and its analogues might be underestimated in some countries. 
Fentanyl-related deaths decreased markedly in Estonia and Sweden in 2018.  
New psychoactive substances: stimulants and benzodiazepines involved in many deaths 
• Most new psychoactive substance-related deaths are reported in the United Kingdom and in 
Turkey (where synthetic cannabinoids largely dominate). Fake and diverted medicines and new 
benzodiazepines are involved in an increasing proportion of drug-related deaths.  
Highlights and concerns  
• When information on post-mortem investigation is available it shows that the proportion of drug-
related deaths involving ‘other opioids’ is increasing in some countries, while the proportion 
involving heroin is decreasing.  
• Cocaine was reported to be involved in an increasing number of deaths in 2018, mainly 
associated with heroin or other opioids. 
• Mortality rates due to overdose are higher in Scotland than in the rest of the United Kingdom or 
in other European countries or the United States. Most deaths in Scotland are related to heroin, 
other opioids and benzodiazepines (etizolam in particular was implicated in more than half of the 
deaths in 2018). 
Implications for public health and for monitoring 
• There are still major limitations and gaps in the monitoring of drug-related deaths. Special 
mortality registers are a key source of information, in particular on polydrug use patterns and on 
prescription opioids and other medicines implicated in deaths.  
• Further triangulation of drug-related deaths and other opioid indicators is needed to consolidate 
estimates of the number of deaths. 
Responding to drug-related deaths 
• While the coverage and diversity of responses to drug-related deaths vary between and within 
countries, drug consumption rooms and take-home naloxone programmes expanded across 
Europe in 2019. The evidence base for their effectiveness is growing. However, more research is 
needed on the population impact of these and other responses.  
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for discussing new trends in and analyses of drug-induced deaths in Europe and beyond 
and responses to them. 
Drug-related mortality is a complex phenomenon. The EMCDDA has defined a drug-related 
death and mortality (DRD) epidemiological indicator, which has two complementary 
components: (i) national, population-based statistics on deaths directly attributable to the use 
of drugs (drug-induced deaths, also known as poisonings or overdoses); and (ii) estimations 
of the overall and cause-specific mortality among high-risk drug users, derived from 
longitudinal cohort studies among drug users (EMCDDA, 2010, 2015, 2019c, 2019d). This 
technical report focuses on the first component. 
Monitoring drug-induced deaths 
The EMCDDA defines drug-induced deaths as those ‘happening shortly after consumption of one or 
more illicit psychoactive drug, and directly related to this consumption’, and these often occur in the 
context of the co-use of other substances such as alcohol or psychoactive medicines (EMCDDA, 
2010). Deaths indirectly associated with drugs (such as those linked to traffic accidents or HIV 
infection) are not considered here. Monitoring drug-induced deaths requires the existence of good-
quality information sources, in particular general mortality registries and/or special mortality registries.  
The EMCDDA protocols define operative criteria for extracting relevant deaths from these registries. 
Extracting from both sources allows cross-validation of the data, but some countries have data 
available from only one source. The general registers provide official statistics with a national 
coverage, and the special registers provide detailed information on the drugs and combinations of 
drugs identified in the post-mortem investigations of the cases. The findings of toxicological 
investigations are reported by countries to the EMCDDA through standardised tools (Fonte and 
annual workbooks). The final decision on the cause of the death is made by the pathologists or 
coroners, in the light of the toxicological findings and other available information. The interpretation of 
data related to drugs is complex because, in most cases, multiple drugs are involved: drugs can be 
reported as ‘mentioned’ or ‘involved’ or as being the ‘cause’ of the death. 
Although most countries are able to fully apply the operative criteria for extracting relevant deaths, 
there are important limitations in drug-induced deaths data, particularly in cumulative European totals 
(EMCDDA, 2019e, 2019f). Of importance are differences between (and within) countries with regard 
to identifying and certifying the cause of death and coding and reporting the number of drug-induced 
deaths. This relates to the quality and frequency of post-mortem investigations, the availability of this 
information for determining the cause of death, the coding system used and the quality of coding, and 
the coverage and quality of the overall reporting system (England, 2017a, 2017b, 2017c; Leifman, 
2017). There are also differences in forensic laboratory capacities and different standard procedures 
for post-mortem toxicological investigation of suspected drug-induced deaths (EMCDDA, 2019g). 
These factors have an impact on the sensitivity of the analysis and hence on the comparability of the 
data within and across countries. Caution is thus advised when interpreting and comparing drug-
induced deaths data over time and between countries. 
More information is available from http://www.emcdda.europa.eu/topics/drug-related-deaths_en. 
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Overdose deaths in Europe: an overview  
It is estimated that at least 8 300 overdose deaths occurred in the European Union as it was 
constituted in 2018. This rises to an estimated 9 200 deaths if Norway and Turkey are 
included, representing a slight decrease compared with the most recent previous estimate of 
9 500 deaths in 2017 (EMCDDA, 2020b). This European figure must be understood as a 
minimum estimation, as there are some countries in which deaths are probably 
underestimated, which will affect the European cumulative totals (see the box above). As in 
previous years, the United Kingdom and Germany together account for around half of the 
total reported deaths in Europe (Figure 1). 
Figure 1. Drug-induced deaths in the European Union, Norway and Turkey: total number (top 
figure) and mortality rates among adults aged 15-64 years, 2018 (bottom map)  
  
 
Note: The latest UK total does not 
include data from Northern Ireland. 
The mortality rate due to drug 
overdoses in Europe (the EU 
Member States, Norway and Turkey) 
in 2018 is estimated at 23.7 deaths 
per million population aged 15-
64 years (this age range is selected 
for computing the mortality rate for 
reasons of comparability across 
indicators and data sets), but this 
varies across countries, with higher 
rates being observed in countries in 
the north of Europe (Figures 1 and 2) 
and among men: 35.0 cases per 
million men aged 15-64 years as 
opposed to 9.5 cases per million 
women aged 15-64 years. 
Source: EMCDDA. Data are for 2018 
or the latest year available.  
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While the UK data as a whole show a progressive increase in drug-induced mortality rates, 
the number of overdose deaths in Scotland has risen rapidly, and the mortality rate is now 
almost 13 times higher than the average in Europe (and above the mortality rate reported in 
comparable data from the United States; see box ‘Overdose deaths in the United States and 
Australia’). The trend in overdose deaths in Estonia is improving (i.e. the numbers are 
falling), and the mortality rate dropped from 130 deaths per million adults in 2017 to 43 
deaths per million population aged 15-64 years in 2018 (see more information later in the 
report) (Figure 2).  
Figure 2. Drug-induced mortality rates among adults (15-64 years) per million: selected trends 
and most recent data 
 
Note: Caution is advised when interpreting and comparing data on drug-induced deaths over time and between 
countries. 
Source: EMCDDA. Trends in the eight countries (plus Scotland, United Kingdom) reporting the highest rates in 
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Demographic characteristics of drug-related fatalities in Europe 
There is an ongoing increase in the reported number of overdose deaths among older age 
groups in Europe. Those aged over 40 years represent a large proportion of all drug-induced 
deaths in many western European countries (Figure 3).  
In 2018, the overall mean age at death due to a drug overdose was 40 years, compared with 
37 years in 2012. Men aged 35-44 years are the worst affected, with a mortality rate of 53.7 
deaths per million, more than double the average for men of all ages (23.7 deaths per million 
men, all ages), and more than three times the highest mortality rate in women (13.9 deaths 
per million women aged 35-44 years).  
Some countries fall outside this general characterisation, and higher levels of drug-related 
deaths occur among younger people. In Turkey and in Hungary, almost one in four deaths 
occurs among those aged less than 25 years, and in Finland, Malta, Slovakia and Poland, 
around one in five deaths occurs among those aged less than 25 years. In comparison, for 
those European countries (1) where data are available, only 8.5 % of the deaths occurred 
among those aged less than 25 years. Overall in Europe, 215 drug-induced deaths among 




(1) Greece is excluded from this calculation, as no age breakdown of the cases was available. 
Overdose deaths in the United States and Australia 
In 2018, 67 367 drug overdose deaths were reported in the United States, and opioids (in particular 
pharmaceutical opioids but also heroin) were involved in 46 802 of these deaths (69.5 %). Almost 
60 % of the opioid overdoses are attributed to fentanyl and its analogues (CDC, 2020; NIDA, 2019), 
and a recent study found that a positive test for fentanyl analogues was reported in one fifth (20.6 %) 
of all opioid-related deaths (O’Donnell et al., 2018). The age-adjusted rate of overdose deaths 
decreased by 4.6 % from 217 per million in 2017 to 207 per million in 2018 (Hedegaard, 2020).  
In 2018 in Australia, 1 740 overdose deaths were reported and opioids were involved in 1 123 of 
these deaths (65 %) (AIHW, 2020). The age-standardised rate of drug-induced deaths was 70 per 
million population, following a continuous increase since 2006, when the rate was 30 deaths per 
million population. Pharmaceutical opioids and heroin are both drivers of the increase. Deaths 
associated with the former occur in older people being treated for chronic pain, who do not have a 
history of injecting drugs, and are more likely to occur in the regions or remote parts of the country. In 
contrast, the deaths associated with heroin are more likely to occur in major cities among younger 
men with a history of injecting drugs. 
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Figure 3. Proportion of drug-induced deaths in people aged less than 25 years (left) and aged 40 years or more (right), 2018 or latest data available 
 
Note: For Germany, 2017 data are used, as a breakdown by age is not available for 2018. Northern Ireland (United Kingdom) data are missing.  
Source: EMCDDA.
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Heroin-related deaths in selected European countries 
Most drug-induced deaths in Europe are attributed to multiple drug toxicity, and several 
drugs are commonly identified in post-mortem examinations. Opioids are involved in most of 
the drug-induced deaths reported in Europe (2).  
In 2019, 22 out of 30 countries reported to varying extents information on the substances 
involved in drug-related deaths. There were 4 149 deaths for which some toxicological 
information was reported, and 2 853 (68 %) involved an opioid. The most common opioid 
involved was heroin, which was identified in 1 281 cases (31 % of the cases with 
toxicological information available or 45 % of the cases with opioids). The second most 
frequently identified opioid was methadone, identified in 696 cases (17 % of all cases with 
toxicological information available or 24 % of the cases with opioids). Buprenorphine was the 
third most common opioid and was identified in 203 cases (5 % of all cases with toxicological 
information available or 7 % of the cases with opioids). Most deaths involved several drugs.  
Extrapolating from the number of deaths for which the toxicology is known to the total 
number of deaths should be done with caution, given possible selection and information 
biases. In summary, where information was available, heroin was the most common opioid 
identified in drug-related deaths reported in 2019 for 2018 or 2017 if no more recent data 
were available. There were at least 3 154 deaths involving heroin (1 873 in England, Wales 
and Scotland and 1 281 in the remaining European countries reporting). The section below 
describes in more detail the situation for heroin-related deaths in selected countries.  
In Germany, heroin/morphine (or its metabolites) is recorded in 405 deaths reported by the 
police, or 45.5 % of the 890 fatal drug poisonings with known toxicology (out of the 1 276 
drug-related deaths in 2018). 
Where recent information was reported on the substances involved in drug-related deaths in 
England and Wales (United Kingdom), heroin/morphine is mentioned in 1 336 deaths, or 
46 % of the 2 917 deaths due to drug misuse registered in 2018 (ONS, 2019) (3). This 
proportion is very likely to be underestimated because of a lack of detailed information on 
death certificates.  
In Scotland (United Kingdom), opioid-related deaths dominate – often linked to polydrug use 
and benzodiazepine use, the latter being associated with 7 out of 10 deaths. Against this 
background, heroin was reported as being implicated in, or having potentially contributed to, 
almost half of all drug-induced deaths in 2018 (537 deaths, 45 %) (National Records of 
Scotland, 2018). Most of the increase in drug-related deaths reported over the last two 
decades is accounted for by deaths among those aged between 35 and 44 years (Figure 4).  
 
(2) See more information on the possible under-reporting of opioid drug-induced deaths the box on the 
opioid multi-indicator pilot project.  
(3) The data on registrations of ‘drug poisoning’ deaths reported by the UK Office for National Statistics for 
2018 are more recent than the data on deaths occurring in 2017 reported by the UK focal point. The denominator 
used here is the ‘number of deaths due to drug misuse’ for England and Wales, and all heroin-related deaths are 
registered as ‘drug misuse’ deaths. The drug misuse definition is closer to the definitions used in other countries 
(including Scotland) than the 4 359 total ‘drug poisonings’. Data reported under the drug misuse definition provide 
a good proxy for the official consolidated number of drug-related deaths to be reported in the coming months by 
the United Kingdom to the EMCDDA. 
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Figure 4. Crude rates of drug-related deaths per 1 000 population by age group, Scotland, 
2000-2018 
 
Source: Data from National Records of Scotland (2019), presented by Andrew McAuley at the expert meeting on 
drug-related deaths, 21-22 October 2019, Lisbon. 
In France, heroin has been involved in around 15-30 % of the drug-related deaths since 
2010. According to the special mortality register (Drames network), heroin was reported in 
135 cases, (31 %) of the deaths in 2017. The proportion of heroin-related cases peaked in 
2015 (30 %), when it was double the proportion in 2012 (15 %) (Figure 5). Similar to 
previous years, in 2017, heroin was reported less frequently than methadone, which was 
found in more than one third of the cases (37 %). The deaths involving heroin among those 
aged 15-49 years appear to be linked to the availability and purity of the drug. The median 
purity of brown heroin seized in France peaked in 2015 at 11 %, more than double the 
median purity in 2012 (5 %).  
Figure 5. Proportion of drug-related deaths (all ages) involving heroin, France, 2011-2017 
 
Source: Special mortality register Drames. Proportions rather than numbers are shown because the number of 
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In Poland, most deaths are related to opioids, primarily heroin. According to the general 
mortality register (Central Statistical Office), there were 202 deaths from overdose reported 
in 2017 in Poland, and toxicological information was available for five of these cases. 
Meanwhile, information on the substances involved in drug-related deaths was available 
from the special register data for the Warsaw region for 2016. According to this source, there 
were 47 deaths reported in 2016 for the region, mostly related to opioids and in particular 
heroin, which was identified in 45 % (n = 21) of the cases (Figure 6).  
Figure 6. Psychoactive substances detected in the post-mortem toxicology examinations 
following deaths from overdose, Warsaw, 2015-2016 (categories are not mutually exclusive 
with more than one drug detected in a single case) 
 
Note: NPS, new psychoactive substances; THC, tetrahydrocannabinol. 
Source: Data from the Forensic Science Department of the Medical University of Warsaw, presented by 
Małgorzata Dalmata (Polish focal point) at the expert meeting on drug-related deaths, 21-22 October 2019, 
Lisbon. 
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Tramadol-related deaths  
Tramadol is an opioid associated with deaths in Europe, although data are reported and 
available in a limited number of countries. In the United Kingdom, where tramadol became a 
controlled drug in June 2014, tramadol was mentioned in 220 deaths (7.4 % of all drug-
related deaths) in England and Wales in 2018, an increase from 185 deaths registered in 
2017 (ONS, 2019). Tramadol was involved in 75 deaths in Norway in 2018, an increase 
compared with the average number recorded over the previous 10 years. In France (2017), 
49 deaths were reported through surveillance of deaths related to analgesia poisoning, and 
11 additional deaths were reported through the special mortality register Drames. Tramadol 
was also involved in 31 deaths reported in Northern Ireland in 2017. In Slovakia, the number 
of tramadol-related deaths was stable between 2017 (11 deaths) and 2018 (13 deaths).  
The medicine is often used in combination with other drugs, and it is therefore difficult to 
assess its contribution to deaths where it is recorded. However, the presence of tramadol 
(and other substances) might be underestimated, as it might not be systematically looked 
Understanding opioid-related deaths in Norway 
In Norway the overall number of overdoses has been stable for 10 years at between 240 and 280 
cases per year. However, there is a decreasing trend in the number of deaths involving heroin and an 
increasing trend in the numbers of deaths involving other opioids such as methadone, oxycodone, 
fentanyl, morphine and codeine. Methadone is prominent and was identified in 23 % of the overdose-
related deaths in Norway in 2017. This occurs against a background of an ageing cohort of patients 
receiving opioid substitution treatment. One third (33 %) of the patients receiving opioid substitution 
treatment in 2017 in Norway were over 50 years old, compared with 16 % in 2010 (see figure below).  
Age distribution of patients receiving opioid substitution treatment, Norway, 2010-2018 
 
Source: Data from the Norwegian Institute of Public Health for 2019, presented by Thomas Clausen at the expert 
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for, or not reported when found. Several countries, including France, the United Kingdom 
and Norway, have reported an increase in the prescription of tramadol and other opioids in 
recent years. In January 2020, France announced the launch of enhanced surveillance of 
tramadol prescriptions. Meanwhile, since 15 April 2020, the maximum duration of a 
prescription was reduced from 12 to 3 months (ANSM, 2020). 
Pregabalin causing concern in some countries 
Pregabalin (a gabapentinoid drug) is causing concern in several countries. It is commonly 
sold under the brand name Lyrica and it is indicated in the treatment of epilepsy, neuropathic 
pain and generalised anxiety disorder. A known side effect of the drug is central nervous 
system depression. There is evidence of misuse, particularly in those with a history of opioid 
and alcohol misuse. Pregabalin and gabapentin are said to be used to ‘boost’ the effects of 
opioids and alcohol (Baird, 2014). 
In Ireland, pregabalin has emerged since 2012, and the medicine was involved in one out of 
five (18 %, or 65) drug-related deaths in 2016 (Figure 7). In all cases, other drugs and 
medicine were implicated with pregabalin. The majority of the deaths (60 %) involved people 
who had a history of mental health issues, and over half were among people who used 
opiates and had had no recent contact with drug services. According to the primary care 
reimbursement service in Ireland, there was an increase of 26 % in prescription rates of 
pregabalin from 2013 to 2016. There was also an increase in the number of deaths (all 
causes) in which pregabalin was implicated and in the number of positive forensic toxicology 
findings for pregabalin (Figure 7).  
In England and Wales (United Kingdom), mirroring the trend in Ireland, the number of deaths 
involving pregabalin was very low until 2012 (four cases), increased to 90 cases in 2015 and 
doubled to 187 cases in 2018. Pregabalin-related deaths have also been reported in Finland 
(42 % of fatal poisonings) and in Sweden (30 % of fatal poisonings) according to a recent 
review of fatal poisoning deaths in the Nordic countries (Simonsen, 2020). Pregabalin-
related deaths may occur in other countries but are either undetected or under-reported. 
Figure 7. Number of deaths involving pregabalin in toxicology and implicated in poisoning 
deaths, Ireland, 2004-2016 
 
Source: National Drug-Related Deaths Index, presented by Suzi Lyons at the expert meeting on drug-related 
deaths, 21-22 October 2019, Lisbon. 
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Pilot project: Opioid multi-indicator analysis/validation to identify and estimate 
possible under-reporting of (opioid) drug-induced deaths  
The usefulness of the drug-related deaths indicator for policymaking is sometimes questioned 
because of concerns that data quality issues may result in under-reporting in some countries. Indeed, 
some countries declare a likely under-reporting of their drug-related deaths in their annual reporting to 
the EMCDDA. In France, under-reporting was assessed through a capture-recapture analysis 
(Janssen, 2011), while in other cases it was identified by comparing different sources (e.g. special 
and general mortality registries, results of mortality cohort studies – in which many deaths were 
codified as of ‘undetermined cause’) or on the basis of expert opinion. Until now, there has been no 
common method of assessing the underestimation of drug-related deaths.  
At the 2018 expert meeting, the EMCDDA presented a model of opioid multi-indicator cross-validation 
that helped to assess under-reporting of drug-related deaths on the basis of other opioid indicators 
(see figure below). The model consists, roughly, of taking the estimated population of high-risk opioid 
users in the country and applying to that population the overdose mortality rate observed among high-
risk opioid users in cohort studies. If there is no cohort study in the country, the overdose mortality 
rates observed in pooled studies are used. The mortality rates applied are also fine-tuned depending 
on the proportion of injectors among high-risk opioid users, the proportion of those people receiving 
opioid substitution treatment and the type of such treatment prescribed in the country (methadone or 
buprenorphine). More details are available in recent publications (EMCDDA, 2019a, 2019f) and in the 
expert presentations at the meeting on drug-related deaths (EMCDDA, 2019b) (1). 
In preparation for the 2019 expert meeting on drug-related deaths, the EMCDDA drafted an ‘opioid 
multi-indicator country profile’ for 11 countries (Czechia, Finland, France, Ireland, Italy, Netherlands, 
Norway, Poland, Portugal, Romania and Sweden), following the common methodology proposed in a 
Reitox document. This preparatory work led to more focused discussions on discrepancies between 
‘expected’ and ‘reported’ numbers of drug-related deaths and on the need for national work.  
During the meeting, experts from Czechia, France, Italy, Norway and Poland discussed and further 
elaborated the results of their national profiles or presented additional analysis. In Czechia, the initial 
marked discrepancy between the ‘expected’ and the reported number of drug-related deaths could be 
explained by the nature of the opioid problem in the country, which is mostly related to buprenorphine 
misuse. The relatively low risk of deaths for people using buprenorphine compared to methdone is 
illustrated by existing studies (Sordo et al., 2017) that show a low overdose mortality in buprenorphine 
clients not receiving treatment (4.6/1 000 per year, compared to 12.7/1 000 per year out of 
methadone treatment). This illustrates the need to have good information on the characteristics of the 
national opioid situation (substance use and patterns of use, including injection and polydrug use) and 
of national mortality data.  
The model estimated drug-related deaths lower than reported deaths in some instances, which could 
be explained by low estimated values for the inputs into the model (number of high-risk opioid users, 
mortality rate) for these countries. Poland presented an unusual situation: the ‘expected’ number of 
drug-related deaths was lower than the reported number, whereas there is thought to be some under-
reporting of drug-related deaths in the country (EMCDDA, 2018b). Similarly, in Norway, the reported 
number of opioid-related deaths was much higher than the ‘expected’ number, possibly because the 
inputs were estimated values. The Norwegian national expert on drug-related deaths discussed the 
possible existence of differentiated sub-populations of opioid users with different patterns of use and 
TECHNICAL REPORT | Drug-related deaths and mortality in Europe: update from the EMCDDA expert network 
17 
 
Cocaine-related deaths in selected European countries 
In recent years, the European drug market has been experiencing an increase in both the 
availability and the purity of cocaine. A rise in powder injection and in the use and injection of 
crack cocaine has also been noted in some countries. These developments have resulted in 
significant public health impacts, with more cocaine-related hospital emergencies and deaths 
and HIV outbreaks linked to cocaine use reported over the past few years (EMCDDA, 
2018a).  
Where information is available, the number of deaths involving cocaine increased in most 
countries in 2018 compared with previous years (Figure 8). Although limited information is 
available on the detailed toxicity of polydrug use, the majority of the deaths related to 
cocaine also involved other drugs, typically opioids.  
mortality risks (people who inject drugs not in treatment, people receiving opioid substitution treatment 
and people using prescription opioids, both legal and illegal) (Clausen, 2008). 
The EMCDDA will encourage national work, including promoting national meetings of the different 
stakeholders (national focal points, national experts on drug-related deaths and high-risk drug use, 
experts in the WHO International Classification of Disease (ICD) coding, forensic services, and 
experts on mortality studies). 
Reported opioid overdose-related deaths per estimated 1 000 high-risk opioid users in 2017 
 
Notes: The estimated number of high-risk opioid users is based on the figures available in the 2018 EMCDDA 
Statistical Bulletin, except for some countries where different or older data was used: Bulgaria (2016), Denmark 
(2009), Estonia (2009), Slovakia (2008) and Sweden (2007). 
The number of opioid overdoses for 2017 (or the closest year for which data are available) is based on the 2018 
EMCDDA Statistical Bulletin. 
Source: Data for drug-related deaths and high-risk opioid users from the 2018 EMCDDA Statistical Bulletin.  
------ 
(1) See details of the EMCDDA expert meeting on the epidemiological indicator drug-related deaths (DRD), 
Lisbon 21-22 October 2019 (http://www.emcdda.europa.eu/meetings/2019/drd). Some presentations are 
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Figure 8. Number of deaths reported with presence or mention of cocaine, selected countries, 
2008-2018 (top) and same countries plus England and Wales (United Kingdom) (bottom) 
 
 
Source: EMCDDA analysis of data reported by the Reitox network of national focal points through the annual 
standard tables and workbooks. The data for Spain come from six cities. The data for England and Wales come 
from the UK Office for National Statistics. 
In England and Wales (United Kingdom), the number of deaths involving cocaine almost 
doubled over 3 years, from 320 in 2015 to 637 in 2018 (representing 22 % of the total drug 
misuse-related deaths in 2018) (ONS, 2019). Meanwhile the number of deaths involving any 
opiate increased, but to a lesser extent, from 1 989 in 2015 to 2 208 in 2018.  
In France, cocaine was present in over one quarter (26 %) of the deaths reported in 2017 
through the Drames special register, doubling the proportion compared with 2015 (13 %). In 
Ireland there was an increase in the number of deaths in which cocaine was implicated, 
rising from 42 deaths in 2016 to 53 in 2017. Most of the cocaine-related deaths in 2017 were 
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In Spain in 2017, half of the deaths (94/189) reported in six large cities (4) involved cocaine. 
One third of these cocaine-related deaths (36) involved other drugs, including opioids, and 
another third (33) involved other drugs without opioids. Only six cases involved cocaine 
alone, 10 involved cocaine and alcohol alone and nine involved cocaine and opioids alone. 
More than half (52/94) involved alcohol (independently of other drugs). The number of 
deaths involving cocaine was stable in 2018 (92 cases). 
In Portugal, the recent increase in the number of deaths involving cocaine was mirrored by 
an increase in the number of deaths involving heroin (Figure 9). In many cases, both drugs 
were identified in post-mortem analysis. There were 25 deaths involving cocaine in 2018, 
and most (19) also involved an opioid (alone in eight cases or with another drug in 11 
cases). Alcohol was found in seven cases (independently of the presence of any other 
substance). Part of the increase could be due to an improvement in the quality of the data, 
made possible by the automated coding of the cause of deaths in Portugal.  
Figure 9. Number of mentions of cocaine and of heroin in post-mortem analysis of drug-related 
deaths, Portugal, 20112018  
 
Source: Instituto Nacional de Medicina Legal (INML), Portugal, presented by Mario Dias at the expert meeting on 
drug-related deaths, 21-22 October 2019, Lisbon. 
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Special focus: a European overview of deaths related to new 
psychoactive substances 
New psychoactive substances (NPS) include a wide range of substances of different 
pharmacological groups (see box ‘New psychoactive substances’) that have emerged since 
2005 on to the European drug market and have been causing considerable concern. The 
EMCDDA, together with Europol, has a key role in identifying, monitoring and assessing 
these substances. By the end of 2018, 730 NPS had been identified and monitored by the 
European Union Early Warning System (EU EWS) on new psychoactive substances since 
its implementation in 1997. Just over half of these (390 out of 730) NPS were found at least 
once in biological or other samples in Europe in 2018 (EMCDDA, 2019c).  
In 2019 the EMCDDA conducted the first epidemiological overview of NPS-related deaths in 
Europe, covering the period 2016-2017. The main source of data for this review was the 
structured annual national reporting to the EMCDDA from the 28 EU countries, Norway and 
Turkey (2017 and 2018 Workbooks on harms and harm reduction), the EMCDDA Statistical 
Bulletins for 2018 and 2019 (EMCDDA, 2019f) and the results of formal ‘risk assessments’ 
on NPS conducted in 2017 and 2018 (EMCDDA, 2020c). In some cases the information was 
complemented with data reported through the EU EWS (EMCDDA, 2020a), which, although 
providing complementary information, has different purposes and is not directly comparable. 
Most countries (27 in 2016 and 24 in 2017) provided information on drug-related deaths in 
their workbooks and were included in the analysis.  
Between 2016 and 2017 just over half of the countries (16) reported at least one death in 
which an NPS was involved, 14 countries in 2016 (997 cases) and 12 countries in 2017 
(1 310 cases). The increase between 2016 and 2017 was mainly related to the increase of 
188 cases in Turkey (synthetic cannabinoids) and, to a lesser extent, to increases in the 
number of cases involving new benzodiazepines (an increase of 57) and new opioids (an 
increase of 45) in the United Kingdom (Figure 10). 
Mapping forensic toxicology services in Europe – preliminary findings 
Following on from recently published work (EMCDDA, 2019g), a review was conducted in 2019-20 to 
map and understand the organisation of the forensic services in charge of toxicology investigations in 
drug-related deaths in Europe. Toxicologists from 25 countries provided the information requested. In 
10 countries – Cyprus, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta and 
Sweden – there is a centralised system whereby one institution is in charge of investigating cases of 
suspected drug-related deaths. In Portugal, the national institution, Instituto Nacional de Medicina 
Legal, coordinates all the analyses carried out for the country at three sites: Lisbon, Coimbra and 
Porto. In other countries, from two to around 30 laboratories are involved in the post-mortem 
toxicological investigation of suspected drug-related deaths. Some of the laboratories handle more 
than 1 000 post-mortem cases each year, whereas others handle fewer than 10 cases per year.  
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Figure 10. Number of NPS-related deaths in countries that reported 10 or more deaths with at 
least one NPS involved, 2016-2017 
 
Source: EMCDDA, presented by Hugo Lopez, Spain, at the expert meeting on drug-related deaths, 21-22 
October 2019, Lisbon. 
 
Combining the information from 2016 and 2017, an NPS was involved in 14.0 % (2 307) of 
all drug-related deaths with known toxicology (16 491 for 2016 and 2017). One of the main 
findings of the review was that most of the NPS-related deaths in 2016/2017 (74.8 %) were 
concentrated in two countries and in most cases related to two types of substances: Turkey 
(synthetic cannabinoids) and the United Kingdom, in particular Scotland (new 
benzodiazepines, primarily etizolam). As an illustration, if in 2017 novel benzodiazepines 
from the United Kingdom (340) and synthetic cannabinoids from Turkey (564) were 
excluded, only 406 out of 7 385 deaths (with known toxicology) in which NPS were present 
(5.5. %) remained in Europe. In 2016, the proportion was 3.7 % (337 out of 9 106 with 
known toxicology). There were no indications that NPS reporting in these two countries was 
particularly different from any others.  
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There were substantial differences in the proportion of drug-related deaths involving NPS 
across countries, as reported in the EMCDDA workbooks. According to this source, in 2017 
in Turkey, NPS were present in 60 % of the drug-related deaths (565/941) and in Hungary – 
although the numbers are much smaller – in 42 % of the deaths (14/33). In four more 
countries, 10-25 % of the deaths involved an NPS (Estonia, Finland, Belgium and the United 
Kingdom). Romania and Poland (Warsaw) reported that an NPS was involved in over 15 % 
of all drug-related deaths in 2016, although in Romania the proportion was substantially 
lower in 2017, and in Poland there was no information available for that year (Figure 11). 
New psychoactive substances 
What is a new psychoactive substance (NPS)? 
An NPS is defined as ‘a new narcotic or psychotropic drug, in pure form or in preparation, that is not 
controlled by the United Nations drug conventions, but which may pose a public health threat 
comparable to that posed by substances listed in these conventions’ (Council of the European Union, 
2017; EMCDDA, 2020a). This definition is legal (controlled or not) and not medical or 
pharmacological. NPS are notified through the EU EWS on new psychoactive substances, which is 
operated by the EMCDDA and Europol (EMCDDA, 2020a). In principle, once an NPS is controlled, it 
should no longer be considered an NPS. However, in this report, and in particular in this overview, all 
substances that have been notified through the EU EWS are included, regardless of their current legal 
status. 
What is an NPS-related death?  
It is a death in which exposure to an NPS is confirmed from biological (post-mortem) samples. The 
presence of a drug (including NPS) in post-mortem toxicological analysis does not imply that the 
substance can be considered the main cause of death or even a contributory factor. The causality is 
established by the experts who conduct the post-mortem investigations on the basis of all the 
information available. As an example, in Scotland, in most cases in 2017 in which the NPS etizolam 
was found, opioids were also present, and in only seven cases was etizolam the only substance 
implicated. However, without the contribution of etizolam (and often alcohol) a number of opioid-
related deaths may not have occurred. EMCDDA ‘risk assessments’ determine whether a substance 
can be considered the cause of a death or likely to have contributed to a death using an expert rating 
system called the ‘toxicological significance score’ (TSS) (Elliott et al., 2018).  
Limitations and strengths of monitoring NPS-related deaths  
Some under-detection of NPS-related deaths is likely, as many of the 730 NPS monitored are not 
routinely screened for in laboratories. However, many European countries are able to identify NPS-
related deaths and report these cases to the EU EWS and through routine annual reporting.  
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Figure 11. Proportion of the drug-related deaths with an NPS involved: countries reporting the 
presence of an NPS (causal or contributory role) in 5 % or more of all drug-related deaths with 
known toxicology, 2016-2017  
Note: For Poland, 2016 data were available only for Warsaw and an NPS was present in 7 out of 47 cases. There 
was no information available for 2017.  
 
The United Kingdom information is of particular interest because of the high overall number 
of drug-related deaths (3 429 in 2017) and the identification of NPS from several 
pharmacological groups in a diversified drug market. In 2017, 12.8 % (439) of the deaths 
involved at least one NPS. Out of the 439 deaths reporting the presence of an NPS, the 
majority (77.4 %, 340 cases) involved new benzodiazepines, in particular etizolam (68.3 %, 
300 cases), and all of them occurred in Scotland and in most cases also involved opioids 
(Figure 12 and Table 1). 
Turkey Hungary Estonia Finland Sweden Belgium UK Romania Austria Lithuania Germany Poland Allcountries
2016 42.4 44.8 21.1 17.5 16.2 8.3 10.6 21.1 1.4 0.0 5.7 14.9 11.4
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Figure 12. Overall number of deaths in which NPS were present at post-mortem investigation, 
and number of deaths for selected NPS, United Kingdom, 2016-2017  
 
Note: Cases from Northern Ireland not included (breakdown by NPS group not available). Totals: 7 cases (2016) 
and 12 cases (2017). Cases involving gamma-hydroxybutyrate (GHB) (23 in 2016 and 17 in 2017) were 
excluded.  
Source: EMCDDA, presented by Hugo Lopez at the expert meeting on drug-related deaths, 21-22 October 2019, 
Lisbon. 












104 8 6 51 (1) 35 4 
Scotland 335 0 334 (2) 0 0 1 
Northern 
Ireland (3) 
n.a. n.a. n.a. n.a. n.a. n.a. 
Total United 
Kingdom 
439 8 340 51 35 5 
(1) Most (in 2017 especially) were fentanyl analogues, but there have been other opioid NPS-related deaths. 
(2) Including 300 involving etizolam. 
(3) Northern Ireland not included (12 cases), as no breakdown by substance was possible. Cases involving 
gamma-hydroxybutyrate (GHB) (17) were excluded.  
Source: Personal communication from Martin White (UK focal point).  
Turkey reported a high number of deaths in which NPS (almost exclusively synthetic 
cannabinoids) were present at post-mortem investigation. In 2016, synthetic cannabinoids 
were present in 98.9 % (373) of the 377 deaths with presence of NPS and in 2017 in 99.8 % 
(564) of 565 deaths with presence of NPS. Severe and fatal acute toxicity of synthetic 
cannabinoids has been described in several systematic reviews, and major complications 
include cardiovascular events (myocardial infarction, ischaemic stroke and emboli), acute 
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paranoia, self-harm/suicide ideation). In 2016, FUB-AMB and 5F-ADB were the two synthetic 
cannabinoids most frequently found in the toxicological analysis of overdose deaths in 
Turkey. There is limited information on the Turkish drug situation, which may explain these 
unusual figures, but different sources, including hospital emergency data, support their 
plausibility (Çoban, 2014; Aksel et al., 2015; Anonymous, 2017; Caliskan et al., 2018).  
In Germany, 75 deaths with NPS present at post-mortem investigation were reported (5.8 % 
of all drug-related deaths) in 2017 and 25 deaths in 2018 (1.9 %) 
Fentanyl and fentanyl analogues  
This group of substances deserves particular attention because of their high potency, 
leading to a high risk of fatal overdose. In Europe, fentanyl and fentanyl analogues are 
usually found in the same countries and in some cases they are found together in post-
mortem investigations. Since 2017, the EU EWS has responded to seven new fentanyl 
derivatives posing health concerns at the EU level, and all seven are now under international 
control. 
On the basis of the review of data on NPS received by the EMCDDA, in 2016 and 2017 
there were, respectively, 326 and 333 deaths involving fentanyl, and 141 and 242 deaths 
involving fentanyl analogues reported. Thirteen countries reported cases, and Estonia, 
Germany, Sweden, the United Kingdom and – with lower numbers – Finland accounted for 
most of the cases reported, for both fentanyl and fentanyl analogues.  
Between 2017 and 2018 Sweden, Estonia and Germany reported marked decreases in the 
numbers of deaths related to fentanyl and fentanyl analogues, whereas in Finland an 
increase in fentanyl-related deaths was reported, although the numbers were small (from 4 
to 11 cases). Fentanyl and its derivatives are usually detected in extremely low 
concentrations, which may make their detection difficult in some laboratories. In addition to 
under-detection, under-reporting of cases related to fentanyl and fentanyl analogues is 
possible in some countries. 
Etizolam: concern around new benzodiazepines in Scotland 
Benzodiazepines are a family of psychoactive medicines commonly prescribed for anxiety 
disorders, insomnia, muscle spasms and seizures. They are a risk factor for fatal drug 
overdose because of their strong depressant effect on the central nervous system, which 
can potentiate the respiratory depression caused by heroin and other opioids. In addition to 
prescription benzodiazepines, NPS belonging to the benzodiazepine class, which are not 
controlled under international drug control laws, are available on the European drug market.  
The rate of high-risk drug use is higher in Scotland than anywhere else in Europe, and most 
of the increase is accounted for by opioid-related deaths involving etizolam and to a lesser 
extent deaths involving diazepam and alprazolam (Figure 13). Etizolam belongs to the group 
of benzodiazepines. It was until 2020 classified as a new psychoactive substance (see box 
‘Etizolam’). Etizolam is readily available online and at street level.  
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Figure 13. Number of mentions of benzodiazepine, by substance, in drug-related deaths in the 
period 2007-2018 and proportion of cases involving etizolam among the 1 187 cases in 2018, 
Scotland  
 
Source: Data from the National Records of Scotland (2019), presented by Andrew McAuley at the expert meeting 
on drug-related deaths, 21-22 October 2019, Lisbon. 
Social determinants such as living in deprived areas, unemployment and poverty are also 
linked to drug overdose, and research indicates that age-standardised rates for drug-related 
deaths among young adults rose during the 1990s in Scotland due to an increased risk of 
drug-related deaths in the cohort born between 1960 and 1980, especially for men living in 
the most deprived areas (Parkinson et al., 2018). The study concluded that this cohort effect 
is consistent with the hypothesis that exposure to the changing social, economic and political 
contexts of the 1980s created a delayed negative health impact. As described for other 
countries where data are available, polydrug use is the norm among high-risk drug users in 
Scotland, where only 15 % (178/1187) of drug-related deaths in 2018 involved a single 
substance. Heroin, benzodiazepines and alcohol were a typical combination.  
A number of benzodiazepines are sold as ‘street Valium’ and, while they may have a similar 
appearance to Valium tablets, some were found to contain diclazepam, other new 
benzodiazepines, a mixture of etizolam and the synthetic opioid U-47,700, or U-47,700 on its 
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In summary, although NPS are found in a significant minority of drug-related deaths in 
Europe (14 % in 2016/2017), most of them are disproportionately concentrated in only two 
countries and related to only two substance groups. These deaths are concentrated in 
specific populations: chronic opioid users in the United Kingdom, in particular in Scotland, 
and a poorly understood population of synthetic cannabinoid users, mainly young men, in 
Turkey. Leaving aside these two groups of deaths, only 4-5 % of drug-related deaths in 
Europe in 2016-2017 were related to NPS, although possibly there is some underestimation 
due to analytical challenges. The number of deaths with fentanyl and fentanyl analogues 
present at post-mortem investigation is relatively low in Europe as a whole, but they are 
concentrated in a limited number of countries, and in some of them they account for a 
relevant proportion of drug-related deaths. Despite a substantial decrease in fentanyl-related 
deaths in Estonia, Germany and Sweden in 2018 compared with 2017, the phenomenon 
presents a significant risk of harm and should be followed closely. 
Responding to drug-related deaths 
Reducing overdose morbidity and mortality is a major public health challenge in Europe. A 
broader public health response in this area aims to reduce vulnerability among high-risk drug 
users, especially by removing barriers and making services accessible and by empowering 
them to take fewer risks (EMCDDA, 2013). In recent years, some European countries (e.g. 
Norway and Sweden) have developed national overdose prevention strategies, and specific 
inquiries into drug overdose have been conducted in the United Kingdom (ONS, 2018). 
An overview of other responses to drug-related deaths, including retention in opioid 
substitution treatment, which has a strong protective effect, is available at the EMCDDA’s 
online Best practice portal and in the European guide Health and Social Responses to Drug 
Problems (EMCDDA, 2017). Updates on two key intervention types, drug consumption 
rooms and take-home naloxone, are presented below. 
Etizolam 
Etizolam is a thienodiazepine derivative, which is a benzodiazepine analogue. Commercialised as 
medicine in a few countries (Japan, India and Italy), its clinical effect is similar to that of 
benzodiazepines – as a benzodiazepine receptor agonist (amnesic, anxiolytic, anticonvulsant, 
hypnotic, sedative and skeletal muscle relaxant). The usual dosage is one tenth of that of diazepam 
(0.5 mg compared with 5 mg) and etizolam is clinically 10 times more active for the same weight. 
However, the median lethal dose (LD50) of etizolam is 4 300 mg/kg (orally) and diazepam is more 
lethal on its own (WHO, 2019a). The deaths related to etizolam have to be considered in the context 
of polydrug use and the substance contributing to fatal outcomes in combination with other central 
nervous system depressants such as opioids and (often) alcohol and the risk increasing with the 
amount ingested (number of pills). Until now the substance has not been controlled under the United 
Nations drug conventions, and therefore it has been considered a new psychoactive substance. In 
November 2019, the WHO recommended that etizolam be placed in Schedule IV of the 1971 
Convention on Psychotropic Substances (WHO, 2019b). This was confirmed at a meeting of the 
Commission on Narcotic Drugs in March 2020.  
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Drug consumption rooms  
Drug consumption facilities, where illicit drugs can be used under the supervision of trained 
staff, have been operating in Europe for 35 years. These facilities primarily aim to reduce the 
acute risks of disease transmission through unhygienic injecting practices, prevent deaths 
from drug-related overdoses and connect high-risk drug users with addiction treatment and 
other health and social services. Eight EU countries (Belgium, Denmark, Germany, Spain, 
France, Luxembourg, Netherlands and Portugal) Norway, Switzerland and Ukraine (5), as 
well as Canada, Australia and Mexico, have established such facilities as part of an 
integrated response to specific local problems.  
Research shows that, through supervised drug consumption rooms, contact with hard-to-
reach populations of people who use drugs, especially marginalised groups and those who 
use drugs on the streets or in other risky settings, with a high burden of premature mortality 
can successfully be established. The analysis of two prospective cohort studies in 
Vancouver, involving at baseline 811 people who inject drugs and tracking their development 
over more than 10 years, showed that frequent use of such facilities was associated with a 
lower risk of death, independent of relevant confounders (Kennedy et al., 2019). 
Furthermore, these facilities reduce injecting-related infections by providing a hygienic 
environment, enhance safer injecting practices, especially among their regular users, and 
promote access to social and health care and drug treatment. In response to their goal to 
improve public amenity in areas surrounding urban drug markets, clear reductions in drug 
use in public places and in drug-related litter have been documented (Kennedy et al., 2017; 
Belackova et al., 2019). At the same time, the operation of supervised consumption facilities 
has been shown to have a neutral effect on drug-related crime (Wood et al., 2006), and 
there appears to be little basis for concern about other adverse effects (Caulkins et al., 
2019).  
In 2019, 78 drug consumption rooms were in operation in the EU and a total of 17 facilities 
function in nine Swiss and two Norwegian cities (see Figure 14). This number does not 
include the facility in Sumy in the Ukraine and it is not shown in Figure 14. 
 
(5) Information on Switzerland from Infodrog; information on Ukraine from Alliance for Public Health. 
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Figure 14. Geographical distribution of supervised consumption facilities in the EU, Norway 
and Switzerland 
 
Sources: Data for the EU from EMCDDA national focal points. Data for Switzerland from Infodrog.  
Take-home naloxone programmes  
Naloxone is an opioid antagonist medication used worldwide in emergency medicine to 
reverse respiratory depression caused by opioid overdose. Take-home naloxone 
programmes aim to prevent opioid overdose deaths by providing the medication to potential 
bystanders (e.g. opioid users, their peers and families) and training them to recognise an 
overdose and to intervene using naloxone. The medication is available as an injectable 
solution in ampoules or pre-filled syringes and, since recently, as an intranasal spray. 
In 2019, naloxone distribution initiatives were reported to exist in 12 countries: Austria, 
Denmark, Estonia, France, Germany, Ireland, Italy, Lithuania, Norway, Spain (Catalonia), 
Sweden and the United Kingdom (Figure 15). In 2018, the legal framework for establishing 
such programmes was created in Cyprus and preparatory steps for introducing naloxone 
were taken in Finland (EMCDDA, 2013, 2017, 2020d). 
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Figure 15. Take-home naloxone programmes in Europe, 2019 
Source: EMCDDA Reitox reporting 2018/2019. 
A new EMCDDA initiative to support countries in their response to preventing drug-related 
deaths, in particular from opioid overdose, is under way. The main objectives of the initiative 
are to improve the monitoring of the situation and responses ‘landscape’ and to develop new 
tools and materials to inform practice and policy about how to improve the prevention of 
drug-related deaths. In this context, barriers and facilitators to take-home naloxone 
programmes have been analysed (Breidahl, 2019). Barriers or facilitators were grouped as 
follows: system-level barriers, including regulatory and legal obstacles, lack of advocacy, 
community stigmatisation of drug users and lack of funding; provider-level barriers to 
providing take-home naloxone, including high staff turnover and workload; and barriers at 
the level of first responders (deliverers), including lack of awareness/education about 
naloxone, and issues limiting practical access to the medication and its use. Identifying and 
tackling regulatory and legal barriers to take-home naloxone programmes, misconceptions 
and knowledge gaps, as well as the impact of drug-related stigma among the general 
population, providers and first responders are important steps to improving the availability of 
take-home naloxone. Removing some barriers requires changes in national regulatory 
systems, while others can be solved by increasing staff and clients’ knowledge and 
implementing simple changes in practice. Materials and tools accompanying this initiative 
will be described in the second edition of the EMCDDA’s European guide Health and Social 
Responses to Drug Problems (EMCDDA, 2017), which currently is under preparation. 
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